• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

激动剂和拮抗剂结合的腺苷 A3 受体复合物的预测结构。

Predicted structures of agonist and antagonist bound complexes of adenosine A3 receptor.

机构信息

Division of Chemistry and Chemical Engineering, Materials and Process Simulation Center MC139-74, California Institute of Technology, Pasadena, California 91125, USA.

出版信息

Proteins. 2011 Jun;79(6):1878-97. doi: 10.1002/prot.23012. Epub 2011 Apr 12.

DOI:10.1002/prot.23012
PMID:21488099
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3092833/
Abstract

We used the GEnSeMBLE Monte Carlo method to predict ensemble of the 20 best packings (helix rotations and tilts) based on the neutral total energy (E) from a vast number (10 trillion) of potential packings for each of the four subtypes of the adenosine G protein-coupled receptors (GPCRs), which are involved in many cytoprotective functions. We then used the DarwinDock Monte Carlo methods to predict the binding pose for the human A(3) adenosine receptor (hAA(3)R) for subtype selective agonists and antagonists. We found that all four A(3) agonists stabilize the 15th lowest conformation of apo-hAA(3)R while also binding strongly to the 1st and 3rd. In contrast the four A(3) antagonists stabilize the 2nd or 3rd lowest conformation. These results show that different ligands can stabilize different GPCR conformations, which will likely affect function, complicating the design of functionally unique ligands. Interestingly all agonists lead to a trans χ1 angle for W6.48 that experiments on other GPCRs associate with G-protein activation while all 20 apo-AA(3)R conformations have a W6.48 gauche+ χ1 angle associated experimentally with inactive GPCRs for other systems. Thus docking calculations have identified critical ligand-GPCR structures involved with activation. We found that the predicted binding site for selective agonist Cl-IB-MECA to the predicted structure of hAA(3)R shows favorable interactions to three subtype variable residues, I253(6.58), V169(EL2), and Q167(EL2), while the predicted structure for hAA(2A)R shows weakened to the corresponding amino acids: T256(6.58), E169(EL2), and L167(EL2), explaining the observed subtype selectivity.

摘要

我们使用 GEnSEMBLE 蒙特卡罗方法,根据中性总能量 (E) 预测了四个腺苷 G 蛋白偶联受体 (GPCR) 亚型中每一种的大量 (10 万亿) 潜在包装的 20 个最佳包装的集合 (螺旋旋转和倾斜)。我们随后使用 DarwinDock 蒙特卡罗方法预测了人 A(3) 腺苷受体 (hAA(3)R) 对亚型选择性激动剂和拮抗剂的结合构象。我们发现,所有四种 A(3) 激动剂都稳定了 apo-hAA(3)R 的第 15 低构象,同时也与第 1 位和第 3 位结合紧密。相比之下,四种 A(3) 拮抗剂稳定了第 2 位或第 3 位的最低构象。这些结果表明,不同的配体可以稳定不同的 GPCR 构象,这可能会影响功能,使具有独特功能的配体的设计复杂化。有趣的是,所有激动剂都导致 W6.48 的反式 χ1 角,而其他 GPCR 上的实验与 G 蛋白激活相关,而所有 20 种 apo-AA(3)R 构象在其他系统中与无活性 GPCR 相关的实验中都具有 W6.48 gauche+ χ1 角。因此,对接计算确定了与激活相关的关键配体-GPCR 结构。我们发现,选择性激动剂 Cl-IB-MECA 预测结合位点与 hAA(3)R 的预测结构显示出与三个亚型可变残基 I253(6.58)、V169(EL2)和 Q167(EL2)的有利相互作用,而 hAA(2A)R 的预测结构显示与相应的氨基酸的相互作用减弱:T256(6.58)、E169(EL2)和 L167(EL2),解释了观察到的亚型选择性。

相似文献

1
Predicted structures of agonist and antagonist bound complexes of adenosine A3 receptor.激动剂和拮抗剂结合的腺苷 A3 受体复合物的预测结构。
Proteins. 2011 Jun;79(6):1878-97. doi: 10.1002/prot.23012. Epub 2011 Apr 12.
2
Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor.激动剂和拮抗剂的对接研究表明了A3腺苷受体的激活途径。
J Mol Graph Model. 2006 Dec;25(4):562-77. doi: 10.1016/j.jmgm.2006.05.004. Epub 2006 May 9.
3
Topological sub-structural molecular design (TOPS-MODE): a useful tool to explore key fragments of human A3 adenosine receptor ligands.拓扑亚结构分子设计(TOPS-MODE):探索人A3腺苷受体配体关键片段的有用工具。
Mol Divers. 2016 Feb;20(1):55-76. doi: 10.1007/s11030-015-9617-z. Epub 2015 Jul 24.
4
Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary.细微的化学变化跨越激动剂和拮抗剂的界限:新的 A 腺苷受体同源模型和结构网络分析可以预测这一界限。
J Med Chem. 2021 Sep 9;64(17):12525-12536. doi: 10.1021/acs.jmedchem.1c00239. Epub 2021 Aug 26.
5
Molecular modeling study on potent and selective adenosine A(3) receptor agonists.关于强效和选择性腺苷 A(3)受体激动剂的分子建模研究。
Bioorg Med Chem. 2010 Nov 15;18(22):7923-30. doi: 10.1016/j.bmc.2010.09.038. Epub 2010 Sep 22.
6
Structural Probing and Molecular Modeling of the A₃ Adenosine Receptor: A Focus on Agonist Binding.A₃ 腺苷受体的结构探测与分子建模:聚焦于激动剂结合
Molecules. 2017 Mar 11;22(3):449. doi: 10.3390/molecules22030449.
7
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.A₃腺苷受体调节剂的药物化学:药理活性及治疗意义
J Med Chem. 2012 Jun 28;55(12):5676-703. doi: 10.1021/jm300087j. Epub 2012 Apr 17.
8
Fragment-Based Discovery of Subtype-Selective Adenosine Receptor Ligands from Homology Models.基于片段从同源模型中发现亚型选择性腺苷受体配体
J Med Chem. 2015 Dec 24;58(24):9578-90. doi: 10.1021/acs.jmedchem.5b01120. Epub 2015 Dec 8.
9
Structural Characterization of Agonist Binding to an A Adenosine Receptor through Biomolecular Simulations and Mutagenesis Experiments.通过生物分子模拟和突变实验研究激动剂与 A 腺苷受体的结合结构。
J Med Chem. 2019 Oct 10;62(19):8831-8846. doi: 10.1021/acs.jmedchem.9b01164. Epub 2019 Sep 27.
10
Polypharmacology of N-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and Related A Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) γ Partial Agonist and PPARδ Antagonist Activity Suggests Their Antidiabetic Potential.N-(3-碘苄基)腺苷-5'-N-甲基脲苷(IB-MECA)及相关A类腺苷受体配体的多药理学特性:过氧化物酶体增殖物激活受体(PPAR)γ部分激动剂和PPARδ拮抗剂活性提示其抗糖尿病潜力
J Med Chem. 2017 Sep 14;60(17):7459-7475. doi: 10.1021/acs.jmedchem.7b00805. Epub 2017 Aug 28.

引用本文的文献

1
Steviol rebaudiosides bind to four different sites of the human sweet taste receptor (T1R2/T1R3) complex explaining confusing experiments.甜菊糖苷与人类甜味受体(T1R2/T1R3)复合物的四个不同位点结合,这解释了令人困惑的实验结果。
Commun Chem. 2024 Oct 18;7(1):236. doi: 10.1038/s42004-024-01324-x.
2
Biased β-Agonists Favoring Gs over β-Arrestin for Individualized Treatment of Obstructive Lung Disease.偏向性β激动剂在阻塞性肺病个体化治疗中对Gs的偏好超过β抑制蛋白
J Pers Med. 2022 Feb 22;12(3):331. doi: 10.3390/jpm12030331.
3
Development of enhanced conformational sampling methods to probe the activation landscape of GPCRs.开发增强构象采样方法以探测 GPCR 激活景观。
Adv Protein Chem Struct Biol. 2022;128:325-359. doi: 10.1016/bs.apcsb.2021.11.001. Epub 2021 Dec 20.
4
Identification and characterization of an atypical Gαs-biased βAR agonist that fails to evoke airway smooth muscle cell tachyphylaxis.鉴定和表征一种非典型的 Gαs 偏向性βAR 激动剂,该激动剂不能引起气道平滑肌细胞的快速脱敏。
Proc Natl Acad Sci U S A. 2021 Dec 7;118(49). doi: 10.1073/pnas.2026668118.
5
A adenosine receptor activation mechanisms: molecular dynamics analysis of inactive, active, and fully active states.腺嘌呤受体激活机制:非活跃、活跃和完全活跃状态的分子动力学分析。
J Comput Aided Mol Des. 2019 Nov;33(11):983-996. doi: 10.1007/s10822-019-00246-4. Epub 2019 Nov 22.
6
Design, Synthesis and Evaluation of New Indolylpyrimidylpiperazines for Gastrointestinal Cancer Therapy.新型吲哚基嘧啶基哌嗪的设计、合成与评价及其在胃肠道癌症治疗中的应用。
Molecules. 2019 Oct 11;24(20):3661. doi: 10.3390/molecules24203661.
7
Salvianolic acids from antithrombotic Traditional Chinese Medicine Danshen are antagonists of human P2Y and P2Y receptors.丹参抗血栓形成的丹参酚酸是人类 P2Y 和 P2Y 受体的拮抗剂。
Sci Rep. 2018 May 24;8(1):8084. doi: 10.1038/s41598-018-26577-0.
8
Predicting glycosaminoglycan surface protein interactions and implications for studying axonal growth.预测糖胺聚糖表面蛋白相互作用及其对研究轴突生长的意义。
Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):13697-13702. doi: 10.1073/pnas.1715093115. Epub 2017 Dec 11.
9
Structural Probing and Molecular Modeling of the A₃ Adenosine Receptor: A Focus on Agonist Binding.A₃ 腺苷受体的结构探测与分子建模:聚焦于激动剂结合
Molecules. 2017 Mar 11;22(3):449. doi: 10.3390/molecules22030449.
10
Conformational and Thermodynamic Landscape of GPCR Activation from Theory and Computation.基于理论与计算的G蛋白偶联受体激活的构象和热力学图景
Biophys J. 2016 Jun 21;110(12):2618-2629. doi: 10.1016/j.bpj.2016.04.028.

本文引用的文献

1
Flat-Bottom Strategy for Improved Accuracy in Protein Side-Chain Placements.用于提高蛋白质侧链放置准确性的平底策略。
J Chem Theory Comput. 2008 Dec 9;4(12):2160-9. doi: 10.1021/ct800196k.
2
All-atom empirical potential for molecular modeling and dynamics studies of proteins.蛋白质分子建模和动力学研究的全原子经验势。
J Phys Chem B. 1998 Apr 30;102(18):3586-616. doi: 10.1021/jp973084f.
3
Prediction of the three-dimensional structure for the rat urotensin II receptor, and comparison of the antagonist binding sites and binding selectivity between human and rat receptors from atomistic simulations.预测大鼠尾加压素 II 受体的三维结构,并通过原子模拟比较人源和大鼠受体的拮抗剂结合位点和结合选择性。
ChemMedChem. 2010 Sep 3;5(9):1594-608. doi: 10.1002/cmdc.201000175.
4
Predicted 3D structures for adenosine receptors bound to ligands: comparison to the crystal structure.结合配体预测的腺苷受体 3D 结构:与晶体结构的比较。
J Struct Biol. 2010 Apr;170(1):10-20. doi: 10.1016/j.jsb.2010.01.001. Epub 2010 Jan 15.
5
Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.A3腺苷受体的药物化学:激动剂、拮抗剂与受体工程
Handb Exp Pharmacol. 2009(193):123-59. doi: 10.1007/978-3-540-89615-9_5.
6
Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system.含有双环[3.1.0]己烷环系的A3腺苷受体选择性核苷的功能化类似物。
J Med Chem. 2009 Dec 10;52(23):7580-92. doi: 10.1021/jm900426g.
7
Ligand binding and micro-switches in 7TM receptor structures.7TM受体结构中的配体结合与微开关
Trends Pharmacol Sci. 2009 May;30(5):249-59. doi: 10.1016/j.tips.2009.02.006. Epub 2009 Apr 16.
8
Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 5-hydroxytryptamine-4 receptors.与5-羟色胺-4受体的基础组成型和激动剂诱导的激活状态相关的构象转换开关。
Mol Pharmacol. 2009 Apr;75(4):982-90. doi: 10.1124/mol.108.053686. Epub 2009 Jan 23.
9
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.与拮抗剂结合的人A2A腺苷受体的2.6埃晶体结构。
Science. 2008 Nov 21;322(5905):1211-7. doi: 10.1126/science.1164772. Epub 2008 Oct 2.
10
Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system.源自含有双环[3.1.0]己烷环系核苷的选择性A(3)腺苷受体拮抗剂。
Bioorg Med Chem. 2008 Sep 15;16(18):8546-56. doi: 10.1016/j.bmc.2008.08.007. Epub 2008 Aug 7.